Relmada Therapeutics (RLMD) Research & Development (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Research & Development data on file, last reported at $8.1 million in Q1 2026.

• On a quarterly basis, Research & Development fell 32.33% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $23.0 million, a 48.65% decrease from a year earlier, with the FY2025 full-year figure at $26.9 million, down 41.79% from the prior year.
• Research & Development for Q1 2026 stood at $8.1 million, roughly flat from $8.1 million in the prior quarter.
• Over the last five years, Research & Development for RLMD reached as high as $30.9 million in Q2 2022 and fell as low as $2.8 million in Q2 2025.
• Historically, Research & Development has averaged $14.7 million across 5 years, with a median of $12.0 million in 2025.
• Across the five-year window, Research & Development surged 78.38% in 2022 and tumbled 73.7% in 2025, its largest moves.
• Year by year, Research & Development stood at $26.9 million in 2022, then slumped by 45.1% to $14.8 million in 2023, then fell by 25.43% to $11.0 million in 2024, then decreased by 26.61% to $8.1 million in 2025, then grew by 0.19% to $8.1 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $8.1 million in Q1 2026, $8.1 million in Q4 2025, and $4.0 million in Q3 2025.